Resilience Biotechnologies Inc. receives $200 million to expand vaccine manufacturing in Mississauga

Resilience Biotechnologies Inc. receives $200 million to expand vaccine manufacturing in Mississauga

The Government of Canada announced a $200 million investment in Resilience Biotechnologies Inc., a Mississauga-based biomanufacturing facility, to help expand made-in-Canada vaccine solutions. With this investment, the Mississauga facility is expected to manufacture approximately 112 to 640 million doses of mRNA (messenger ribonucleic acid) vaccines per year.

“Investing in vaccine manufacturing is more important now than ever and I’m thankful that the federal government chose to invest in a Mississauga-based facility,” says Mayor Bonnie Crombie. “This investment is evidence that Mississauga is a leading national science hub that supports business development and growth. Through our relationships with biomanufacturing companies, like Resilience Biotechnologies Inc., we can continue to support growth and expansion in this sector.”

Read the full Press Release on our Corporate Website here.